Breadth of T-cell Responses After Heterologous Route Immunological Prime-boost Using Influenza Antigens as a Model System
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2016
At a glance
- Drugs GSK 2321138A (Primary) ; MEDI 3250 (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- 25 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 23 Nov 2015 Status changed from not yet recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 25 Sep 2015 New trial record